Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.936651
Abstract: Several clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) can reduce the risk of cardiovascular events in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Recent reports…
read more here.
Keywords:
sglt inhibitors;
prescription;
glp receptor;
online searches ... See more keywords